What Medical Device Company Reinvented Itself 5 Years Ago?

Trivia Tuesday: What major medical device company reinvented itself in 2018 through nine acquisitions and several strategic venture investments?

Amanda Pedersen

January 9, 2024

1 Min Read
M&A concept illustrated by one big fish opening mouth wide to swallow many small fish.
Image by: PeterHermesFurian / iStock via Getty Images

This week's big M&A news that Boston Scientific has agreed to pay $3.7 billion for Axonics is giving us 2018 vibes.

That was the year Boston Scientific reinvented itself through no less than nine acquisitions and about $6 billion worth of strategic venture investments.

While we await official commentary from Boston Scientific management to find out if we should expect the company's M&A appetite this year to rival that of 2018, let's revisit the company's major deal activity that year.

In November 2018, the company won bragging rights to the biggest medtech M&A news of the year when it announced it would buy BTG for $4 billion, although that deal didn't close until 2019. The London-based company had three key businesses, the largest of which was its interventional medicine portfolio which encompassed several peripheral interventional product lines.

Another noteworthy 2018 M&A from Boston Scientific was its acquisition of Augmenix for a $500 million cash payment upfront and up to $100 million in sales-based milestone payments. Augmenix helped Boston Scientific bolster its urology business with the addition of the SpaceOAR hydrogel, a therapy designed to reduce common side effects that men may experience after receiving prostate cancer radiotherapy. That deal followed Boston Scientific's decision to buy NxThera for $406 million, a deal that also strengthened its urology business.

Boston Scientific's other 2018 acquisitions included nVision for $275 million (counting milestone payments); Claret Medical for $270 million (with milestone payment); Veniti for $160 million (with milestone payments); EMcision (financial details undisclosed); Cryterion Medical for $202 million (not counting the company's previous investment in Cryterion); and Securus Medical Group for $50 million (counting milestone payments).

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like